With a $1.5 million grant, the Michael J. Fox Foundation (MJFF) continues to support Amydis in developing a non-invasive eye tracer that can be used to diagnose Parkinson’s disease in retinal tissue. The MJFF grant — the third given to the pharmaceutical company for this work — is being applied…
News
New scientific evidence supports a link between exposure to toxic environmental factors — pesticides, air pollutants, man-made materials, and more — to an increased risk of developing neurodegenerative diseases, including Parkinson’s. The evidence, which has spearheaded a new research area in neuroscience, was presented at the 147th Annual…
Using simulated images, researchers have developed a method that may allow them to quantify how much dopamine transporter — a protein that pumps the chemical messenger dopamine into cells — there is in brain regions linked to Parkinson’s disease. The method can glean information from a single-photon emission…
Scientists in the United Kingdom have developed a robotic device to aid the diagnosis and treatment of brain disorders, such as Parkinson’s. The device — a soft, flexible catheter and an artificial intelligence (AI)-enabled robotic arm — could help neurosurgeons see deep brain structures and deliver treatments without damaging…
In a mouse model of Parkinson’s disease animals show signs of inflammation in the gut, and treatment with cell therapies that reduce this inflammation help to ease symptoms of Parkinson’s, according to a new study. These results suggest that inflammatory conditions in the gut may contribute to the development…
The U.S. Food and Drug Administration (FDA) has granted NeuroOne Medical Technologies clearance to market its Evo stereoelectroencephalography (sEEG) electrode technology for temporary use of less than 30 days. The device — previously cleared by the FDA for use of less than one day — is used to measure…
People with Parkinson’s disease have generally positive attitudes toward using therapies derived from human embryos, according to a new study based on interviews with patients in Sweden. The study, “Patients’ views on using human embryonic stem cells to treat Parkinson’s disease: an interview study,” was published in BMC Medical Ethics.
To better care for the growing number of people with Parkinson’s disease and their families, the Michael J. Fox Foundation (MJFF) is expanding the size and reach of its global Edmond J. Safra Fellowship in Movement Disorders program. The two-year fellowship supports medical centers in training a new generation of…
A therapeutic mix of exercise, cognitive stimulation and social activity — known as environmental enrichment — eased Parkinson’s disease symptoms and protected brain cells in a mouse model, though to a greater extent in early disease stages, a study reported. Benefits were notably less potent in animals with more advanced…
XPhyto Therapeutics’ generic version of the Neupro patch for Parkinson’s disease is showing that its active ingredient, rotigotine, can be absorbed through the skin in ways similar to the brand-name product, the company announced. Findings, in work using skin from human cadavers and an optimized formula for the generic patch, support…
Recent Posts
- New delivery system guides curcumin to Parkinson’s-affected brain cells
- New $2M MJFF grant backs Parkinson’s walking study at Boston University
- My fear of falling has gotten worse since my Parkinson’s diagnosis
- New compound targets mitochondrial damage in Parkinson’s models
- Environmental factors may impact Parkinson’s disease risk: Dutch study